SSA
STRO icon

Schonfeld Strategic Advisors’s Sutro Biopharma STRO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,680
Closed -$362K – 2486
2024
Q4 		$362K Sell
19,680
-8,680
-31% -$265K ﹤0.01% 1538
2024
Q3 		$981K Sell
28,360
-35,060
-55% -$1.37M 0.01% 1167
2024
Q2 		$1.86M Sell
63,420
-48,890
-44% -$1.93M 0.01% 937
2024
Q1 		$6.35M Buy
112,310
+78,450
+232% +$3.47M 0.04% 550
2023
Q4 		$1.45M Sell
33,860
-1,640
-5% -$52K 0.01% 910
2023
Q3 		$1.23M Sell
35,500
-130
-0.4% -$5.66K 0.01% 956
2023
Q2 		$1.66M Buy
35,630
+1,030
+3% +$51.3K 0.01% 809
2023
Q1 		$1.6M Buy
34,600
+6,220
+22% +$395K 0.02% 765
2022
Q4 		$2.29M Buy
28,380
+23,600
+494% +$1.64M 0.02% 771
2022
Q3 		$265K Sell
4,780
-1,750
-27% -$104K ﹤0.01% 2164
2022
Q2 		$340K Buy
+6,530
New +$365K ﹤0.01% 1588
2021
Q2 		– Sell
-7,161
Closed -$1.63M – 2292
2021
Q1 		$1.63M Sell
7,161
-6,562
-48% -$1.56M 0.02% 724
2020
Q4 		$2.98M Buy
13,723
+8,623
+169% +$1.43M 0.04% 517
2020
Q3 		$512K Buy
+5,100
New +$482K 0.01% 905

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Schonfeld Strategic Advisors's STRO Position: Q1 2025 in Review

Schonfeld Strategic Advisors sold out of Sutro Biopharma (STRO) in Q1 2025, closing a stake of 19,680 shares — an estimated $362K sold.

Schonfeld Strategic Advisors first reported a position in STRO in Q3 2020 and held it in 14 quarters. The position peaked at $6.35M in Q1 2024. 112 funds tracked by Wall St. Rank hold STRO as of Q1 2025.

  • Schonfeld Strategic Advisors reported no remaining Sutro Biopharma position as of Q1 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 19,680 Sutro Biopharma shares in Q1 2025, an estimated $362K.
  • Schonfeld Strategic Advisors first reported a position in Sutro Biopharma in Q3 2020 and held it in 14 quarters.
  • Schonfeld Strategic Advisors's Sutro Biopharma position peaked at $6.35M in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2025, filed 15 May 2025.